Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Molecular Pathways Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer Kenneth J. Pienta and Deborah Bradley Background Recent Advances Prostate cancer continues to be the most common lethal malignancy diagnosed in American men and the second leading cause of male cancer mortality. The American Cancer Society estimates that during 2005, f232,090 new cases of prostate cancer will be diagnosed in the United States and 30,350 men will die of metastatic disease (1). Approximately 1 man in 5 will be diagnosed with prostate cancer during his lifetime, and 1 man in 33 will die of this disease. As the population ages, these numbers are expected to increase. Initially, almost all metastatic prostate cancers require testosterone for growth, and the role of androgen deprivation as a first-line therapy for metastatic prostate cancer has been recognized for more than 60 years (2, 3). Hormone deprivation is accomplished by surgical (orchiectomy) or medical (luteinizing hormone-releasing hormone agonists, antiandrogens) castration. Hormonal therapy leads to remissions lasting 2 to 3 years; however, virtually all patients progress to a clinically androgen-independent state resulting in death in f16 to 18 months (4 – 9). Androgens are primary regulators of normal prostate as well as prostate cancer cell growth and proliferation. During androgen-dependent progression, prostate cancer cells depend on the androgen receptor as the primary mediator of growth and survival (10 – 12). When testosterone enters the cell, it is converted by the enzyme 5a-reductase to its active metabolite, dihydrotestosterone, a more active hormone with a 5- to 10fold higher affinity for the androgen receptor. Dihydrotestosterone binds androgen receptors in the cytoplasm, causing phosphorylation, dimerization, and subsequent translocation into the nucleus, thereby binding to the androgen-response elements within the DNA, with consequent activation of genes involved in cell growth and survival (10). During androgenindependent progression, prostate cancer cells develop a variety of cellular pathways to survive and flourish in an androgendepleted environment. Postulated and documented mechanisms include androgen receptor (AR) gene amplification, AR gene mutations, involvement of coregulators, ligandindependent activation of the androgen receptor, and the involvement of tumor stem cells (Fig. 1; refs. 8, 10 – 14). Authors’Affiliation: Michigan Urology Center, University of Michigan, Ann Arbor, Michigan Received 1/11/06; revised 1/26/06; accepted 1/27/06. Grant support: University of Michigan Prostate Specialized Program of Research Excellence, NIH grant P50CA69568. Requests for reprints: Kenneth J. Pienta, Michigan Urology Center, University of Michigan, 7308 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 481090946. Phone: 734-647-3421; Fax: 734-647-9480; E-mail: kpienta@ umich.edu. F 2006 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-06-0067 www.aacrjournals.org Hypersensitive Pathway. One way in which prostate cancer cells circumvent the effects of androgen blockade is by developing the ability to use very low levels of androgen for growth (14 – 16). Hence, they do not become androgen independent in the classic sense, but rather castration independent. There are several proposed mechanisms that could explain response to lower levels of androgen. One such mechanism is increased expression of the androgen receptor, allowing enhanced ligand binding. The existence of this pathway is supported by studies of hormonerefractory tumors that have shown increased expression of androgen receptor compared with androgen-dependent tumors (14, 17 – 22). Increased production of androgen receptor is likely secondary to gene amplification as a result of mutation or through selective pressure of the androgendepleted environment, causing the cells with fewer androgen receptors to die off and the clonal expansion of cells with more androgen receptor. Chen et al. (14) have shown, through comprehensive gene profiling of seven human prostate cancer xenograft models, that AR gene expression was up-regulated in the progression from androgen-dependent to castration-independent growth. Chen et al. (14) also showed that androgen-independent cells require 80% lower concentrations of androgen than androgen-dependent cells for growth. Increased sensitivity of the androgen receptor to androgens has been proposed as another mechanism for castration independence (15). Using the prostate cancer cell line LNCaP, which has a mutated androgen receptor, Gregory and coworkers have shown high level expression of the androgen receptor, increased stability of the androgen receptor, and enhanced nuclear localization of the androgen receptor in recurrent prostate tumors associated with an increased sensitivity to the growth-promoting effects of dihydrotestosterone. The concentration of dihydrotestosterone required for growth stimulation of androgen-independent cells was 4 orders of magnitude lower than that required for androgen-dependent LNCaP cells (15). A third hypersensitive mechanism proposed is increased local production of androgens by prostate cancer cells themselves. This most likely occurs by increased rate of conversion of testosterone to dihydrotestosterone by increasing 5a-reductase activity (10). Evidence in support of this mechanism includes (a) ethnic groups with higher levels of 5a-reductase activity have a higher rate of prostate cancer (23); (b) after androgen ablation therapy, serum testosterone levels decrease by 95%, but concentration of dihydrotestosterone in prostatic tissue is reduced by only 60% (24); and (c) genes involved in steroid biosynthesis have been found to be overexpressed in recurrent human prostate tumors (22). 1665 Clin Cancer Res 2006;12(6) March 15, 2006 Downloaded from clincancerres.aacrjournals.org on April 30, 2017. © 2006 American Association for Cancer Research. Molecular Pathways Fig. 1. Mechanisms of androgen independence. 1, amplification. Prostate cancer cells develop the ability to use low levels of androgen for survival by increased production of the androgen receptor (AR ; usually by gene amplification), increased sensitivity of the androgen receptor to androgen, and by increased local conversion of testosterone to dihydrotestosterone by 5a-reductase (5aR). 2, promiscuous binding. Mutations of the androgen receptor broaden binding specificity allowing nonandrogenic steroid molecules normally present in the circulation as well as antiandrogens to bind and activate the androgen receptor. 3, outlaw pathway. Nonsteroid molecules activate the androgen receptor by ligand-dependent binding or activate downstream signaling of the androgen receptor by ligand-independent mechanisms [e.g., epidermal growth factor (EGF)]. 4, bypass pathway. Prostate cancer cells develop the ability of survive independent of the androgen receptor. The best known bypass pathway is through modulation of apoptosis by up-regulation of the molecule Bcl-2 by androgen-independent prostate cancer cells which protect them from apoptosis or programmed cell death when they are exposed to lack of testosterone. 5, coregulators. Alterations in the balance between coactivators and corepressors, which function as signaling intermediates between the androgen receptor and the transcriptional machinery, influence androgen receptor activation contributing to ability to respond to lower levels of androgen and alternative mechanisms of activation. 6, stem cell regeneration. Prostate cancer stem cells, which are not dependent on the androgen receptor for survival, continually resupply the tumor cell population despite therapy. Promiscuous Receptor. Although the wild-type androgen receptor is activated only by testosterone and dihydrotestosterone, the specificity of the androgen receptor has been shown to be broadened by mutations. The majority of mutations discovered leading to binding promiscuity are clustered in the ligand-binding domains (25, 26). These mutations allow the androgen receptor to be activated by nonandrogenic steroid molecules normally present in the circulation as well as antiandrogens (10– 12, 14, 27– 31). Such mutations have been shown to be more frequent in androgen-independent prostate cancer cells and form the basis of antiandrogen withdrawal syndromes in which f10% to 30% of patients treated with long-term antiandrogens will show disease regression with drug withdrawal (32– 35). Clin Cancer Res 2006;12(6) March 15, 2006 Outlaw Pathway. It has also been determined that activation of androgen receptor can be accomplished by liganddependent binding of nonsteroid molecules or activation of downstream signaling of the androgen receptor by ligandindependent mechanisms. Growth and proliferation of tumor cells is therefore no longer under androgen control, although the androgen receptor machinery remains active. This type of activation has been coined outlaw activation (10 – 13). Deregulated growth factors, including insulin-like growth factor, keratinocyte growth factor, and epidermal growth factor, and cytokines, including IL-6, have been shown to directly phosphorylate and activate the androgen receptor (36, 37). In addition, it has been shown that androgen receptor– dependent genes can be activated by deregulation of signal 1666 www.aacrjournals.org Downloaded from clincancerres.aacrjournals.org on April 30, 2017. © 2006 American Association for Cancer Research. Development of Androgen-Independent Prostate Cancer transduction pathways (38, 39). For example, overexpression of the receptor tyrosine kinase HER-2/neu has been shown to activate androgen receptor –dependent genes in the absence of a ligand (38, 39). The activation of outlaw pathways spotlights the potential importance of tumor-microenvironment interactions in the development of castration-independent growth (40, 41). Paget (42) recognized that a ‘‘fertile soil’’ was necessary for the successful growth of cancer metastases. For example, many factors contribute to both androgen-dependent and independent growth of prostate cancer in the bone (41). The interaction of prostate cancer cells with bone stromal cells, osteoblasts, and osteoclasts, as well as the remodeling of bone extracellular matrix, results in the release and deregulation of multiple growth factors that the prostate cancer cells can use to become androgen independent. Coactivators and Corepressors. A large number of coactivators and corepressors involved in the regulation of androgen receptor–driven transcription have been identified (43). They function as signaling intermediaries between the androgen receptor and general transcriptional machinery. Alterations in the balance between coactivators and corepressors have been shown to influence androgen receptor activation, although the precise mechanisms remain unknown (10, 44–47). An increase in coactivator levels has been shown in androgen-independent disease (44, 48–51). Coactivator proteins have been shown to enhance the activity of the androgen receptor to alternative ligands, sensitize the receptor to lower levels of native and Fig. 2. Targeting critical pathways and the tumor microenvironment of androgen-independent prostate cancer. Targeted therapies are being developed that block outlaw signal transduction pathways to prevent ligand-independent phosphorylation of the androgen receptor, including agents that inhibit growth factor receptors directly (e.g., epidermal growth factor receptor by gefitinib) or indirectly through inhibition of downstream signal transduction (e.g., inhibition of ras by reolysin or bRaf by BAY43-9006). The bypass pathway is being targeted by chemotherapeutic agents such as docetaxel as well as specific inhibitors of Bcl-2 (gossypol and the antisense molecule G3139) as well as clusterin (the antisense molecule OGX-011). Geldanamycin is an antibiotic that destabilizes heat shock protein 90 and targets the hypoxia pathway as well as the androgen receptor signaling pathway. The tumor microenvironment is now actively targeted by agents which bind bone hydroxyapatite and inhibit osteoclast function, including zoledronate and the radioisotopes samarium and strontium. The signal transduction of supporting cells is being targeted by vascular endothelial growth factor antibodies (endothelial cells) and endothelin-1 (ET-1) receptor antagonists (osteoblasts). Stimulation of the immune system to recognize prostate cancer cells as foreign is being pursued through multiple vaccine strategies (e.g., APC8015, GVAX, and TRICOM-vaccinia). GF, growth factor; VEGF, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; EGFR, epidermal growth factor receptor; ET-R, endothelin receptor; RTK, receptor tyrosine kinase; mTOR, mammalian target of rapamycin. www.aacrjournals.org 1667 Clin Cancer Res 2006;12(6) March 15, 2006 Downloaded from clincancerres.aacrjournals.org on April 30, 2017. © 2006 American Association for Cancer Research. Molecular Pathways nonnative ligands, and to allow ligand-independent activation (44, 52). Bypass Pathway. Alternatively, the androgen receptor pathway can be bypassed completely and prostate cancer cells develop the ability to survive independent of ligand-mediated or non-ligand-mediated androgen receptor activation. The best known bypass mechanism involves modulation of apoptosis. In androgen-dependent prostate cancer cells, androgen receptor activation stimulates cell proliferation and depletion of androgen leads to apoptosis of these cells. Androgen-independent prostate cancer cells have been shown to frequently up-regulate antiapoptotic molecules (53 – 56). Inactivation of the tumorsuppressor gene phosphatase and tensin homologue with subsequent activation of Akt is one way in which androgenindependent prostate cancer cells escape apoptosis in an androgen-depleted environment (12). Another postulated bypass mechanism is the neuroendocrine differentiation of prostate cancer cells (12). Neuroendocrines cells have a low rate of proliferation and are more prevalent in androgenrefractory prostate cancer (12). They also secrete neuropeptides, such as serotonin and bombesin, which can increase the proliferation of neighboring cancer cells, allowing progression in a low-androgen environment (12). Prostate Cancer Stem Cells. In contrast to the stochastic model of tumorigenesis, in which every cell within the tumor is potentially tumor-initiating, the stem cell model of cancer, or the hierarchical model, postulates that only a rare subset of cells are tumorigenic (54). A population of cells comprising 0.1% of prostate tumors, which are CD44+/a2h1/CD133+ and do not express androgen receptors, has been identified and is thought to be prostate cancer stem or progenitor cells (57). Another potential mechanism for survival in the androgen-depleted environment is the presence of prostate cancer stem cells that continually resupply the tumor cell population, despite therapy. Although these cells remain a small percentage of the actual percentage of the tumor, they are not affected by androgen-depletion therapy. These stem cells differentiate into androgen-dependent and independent cells, resulting in the heterogeneous androgen receptor phenotype that is observed in androgen-independent patients (8). Therapeutic Implications Novel Strategies to Target Hormone Refractory Prostate Cancer. Ultimately, understanding the mechanisms is not enough. Understanding the pathways to what we now know as castration-resistant prostate cancer offers specific therapeutic opportunities based on these mechanisms (40, 41, 58). As in many cancers, novel therapies are being approached with two different strategies. The first is the identification of critical pathways and targets. The second is the development of multitargeted approaches that are directed not only at the cancer cell but also at the surrounding microenvironment of the tumor (Fig. 2). Critical Pathways. Bypass pathways that promote cell survival are being targeted with a variety of strategies. Targeting the Bcl-2 molecule-microtubule complex with the agent docetaxel has led to the first shown survival benefit for patients with androgen-independent prostate cancer (58). In a trial involving 1,006 men with hormone refractory prostate cancer, Tannock et al. (59) reported in 2004 that 75 mg/m2 Clin Cancer Res 2006;12(6) March 15, 2006 of docetaxel given every 3 weeks plus daily prednisone led to a median survival rate of 18.9 months, compared with a survival rate of 16.4 months in patients who received 12 mg/m2 of mitoxantrone given every 3 weeks plus daily prednisone (P = 0.009). As compared with the mitoxantrone group, those given docetaxel every 3 weeks had a hazard ratio for death of 0.76 (95% confidence interval, 0.62-0.94; P = 0.009). The every-3-week schedule of docetaxel showed an advantage in median survival when compared with mitoxantrone (18.9 versus 16.4 months; P = 0.009). Docetaxel every 3 weeks plus prednisone therapy also resulted in improvement in pain, a decrease in prostate-specific antigen, and improved quality of life compared with mitoxantrone plus prednisone. G3139 (oblimersen sodium) is an antisense oligonucleotide directed against Bcl-2 mRNA that seems to have clinical activity in conjunction with docetaxel (60). Several trials are under way with the polyphenol gossypol and its derivatives inhibit Bcl-2, Bcl-xL, and cyclin D1 (61). An antisense molecule to clusterin, a prosurvival gene that is up-regulated in androgenindependent prostate cancer, is currently in clinical trials (62). 1,25-Dihydroxycholecalciferol (calcitriol) potentiates the activity of chemotherapeutic agents by causing G0-G1 arrest and inducing apoptosis. The combination of calcitriol and docetaxel seems to have increased antitumor activity as compared with docetaxel alone and is the subject of ongoing investigation (63). Although new chemotherapeutic drugs such as satraplatin and the epothilones are in clinical trials in advanced prostate cancer, the most exciting progress is being made in targeting outlaw signal transduction pathways that are deregulated in prostate cancer (58, 64 – 66). Outlaw pathways often rely on the activation of the tyrosine kinase growth factor receptors. Antibodies and small molecules that target growth factor receptors on prostate cancer cells include those directed against epidermal growth factor receptor (gefitinib, cetuximab, trastuzumab, lapatinib, and erlotinib) and platelet-derived growth factor receptors (imantinib and leflunomide; refs. 41, 67). Other tyrosine receptor pathway inhibitors include BAY439006, reolysin, LErafAON, and GEM 231. Many of these pathways can also be targeted in the supporting cells of the tumor. The now classic example of this is the use of agents that target the vascular endothelial growth factor pathway to interrupt the blood supply to the tumor cells (68). A phase III trial of bevacizumab (Avastin) and docetaxel is being done by the Eastern Cooperative Oncology Group. Another such agent is atrasentan, which targets the endothelin-1 axis in osteoblasts (69). This agent, in combination with docetaxel, is the subject of a phase III trial by the SouthWest Oncology Group. As the role of the androgen receptor in androgenresistant disease has been recognized, it has become a focus of therapeutic development. In focusing on targeting the hypersensitive pathway, one approach has been to try to lower androgen receptor protein levels. Ansamycin antibiotics, such as 17-allylamino-17-demethoxygeldanamycin, have been shown in preclinical models to induce degradation of steroid receptors, including the androgen receptor, by inhibiting heat shock protein 90, a chaperone required for the folding of these proteins, and are currently in phase I trials (70 – 73). In preclinical studies, Eder et al. (74) were able to inhibit androgen receptor expression in LNCaP tumor cells using antisense androgen receptor 1668 www.aacrjournals.org Downloaded from clincancerres.aacrjournals.org on April 30, 2017. © 2006 American Association for Cancer Research. Development of Androgen-Independent Prostate Cancer oligodeoxynucleotides resulting in decreased growth, decreased production of prostate-specific antigen, and increased apoptosis. Further advances are also being made to reduce testosterone beyond the currently known second-line and third-line hormonal agents; it was recognized that much less ligand is needed for androgen receptor activation in hormone-refractory prostate cancer cells (75). A large number of coactivators and corepressors involved in the regulation of androgen receptor – driven transcription have been identified (43). Because it is known that ligand-dependent and ligand-independent androgen receptor transcriptional activity is dependent on coactivator recruitment, modification of these coregulators or their binding targets may be important therapeutically. Peptide antagonists that target specific nuclear receptor coactivator binding surfaces have been developed in the preclinical setting and have been shown to inhibit androgen receptor transcriptional activity by disrupting androgen receptor-coactivator interactions (76). The signal transduction pathways associated with tumor hypoxia has been the subject of intense scrutiny because they involve the outlaw, bypass, and cofactor pathways (77). CCI779 and RAD001 target the mammalian target of rapamycin and upstream regulator of hypoxia-inducible factor 1a (78 – 80). Hypoxia-inducible factor 1a is also regulated through its binding to heat shock protein 90, which prevents its degradation by the proteosome complex (80). Heat shock protein 90 also stabilizes multiple other enzymes that are part of tyrosine kinase signaling cascades, as well as other proteins, such as steroid receptors including the androgen receptor (81). The geldanamycin derivative 17-(allylamino)-17-demethoxygeldanamycin is an antibiotic that inhibits heat shock protein 90 function, leading to proteosome degradation of these multiple signaling targets (77 – 81). Multitargeted Attack of the Cancer Cell and the Tumor Microenvironment. While other molecular targets, including the mitotic kinesins, histone deacetylases, the small-molecule inhibitor suberoylanilide hydroxamic acid, and cyclic GMP phosphodiesterases, are being pursued, the combination of multiple agents that simultaneously attack the tumor and its microenvironment are being developed as well as already being used in the clinic (41, 82, 83). Prostate cancer cells in the bone interact with the extracellular matrix, stromal cells, osteoblasts, osteoclasts, and endothelial cells to coordinate a sophisticated series of interactions to promote tumor cell survival and proliferation (41, 84). The Food and Drug Administration – approved bisphosphonate zoledronic acid binds to the hydroxyapatite of damaged bone and inhibits osteoclast function, leading to a decrease in skeletal related events, such as fractures, in patients with hormone refractory prostate cancer (85, 86). Similarly, the radioisotopes samarium and strontium have been Food and Drug Administration approved for patients with bone metastases because they, too, bind to hydroxyapatite and deliver radiation to the entire tumor microenvironment, damaging not only the cancer cells but all of the supporting cells of the microenvironment (87, 88). The benefits of these agents in decreasing the morbidity of metastatic prostate cancer have been clearly delineated. Agents that deliver radiation to all prostate cancer cells, whether they reside in bone or soft tissue sites, are in clinical trials. Prostatespecific membrane antigen is a transmembrane glycoprotein that is highly expressed by prostate cancers and trials using antibodies to prostate-specific membrane antigen conjugated to multiple different radiopharmaceuticals and chemotherapy agents are under way (89). All of these approaches can be complemented by strategies that exploit the immune system. Several vaccine strategies that either increase the antigenicity of prostate cancer cells or sensitize dendritic cells to the presence of prostate cancer cells are in clinical trials. These include APC8015 (Provenge), an investigational therapeutic vaccine that uses autologous antigen-presenting cells loaded with a recombinant fusion protein of prostatic acid phosphatase linked to a molecule that specifically targets a receptor expressed on the surface of human antigen-presenting cells, GVAX, an autologous tumor vaccine in which cells from the patient’s tumor are transduced in vitro with an engineered adenovirus containing the GM-CSF gene and poxvirus-TRICOM combinations (90 – 92). Conclusion The treatment of hormone-refractory prostate cancer is evolving rapidly. The definition of the multiple mechanisms by which prostate cancer cells can become resistant to castration has led to the identification of several new leads and pathways that are being quickly exploited. Combining this knowledge with a multifaceted attack on the tumor microenvironment that includes therapy involving endothelial cells, osteoblasts, osteoclasts, tumor stroma, and immune modulation should lead to a rapid increase in survival in patients with hormone-refractory prostate cancer in the near future. References 1. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA CancerJ Clin 2005;55:10 ^ 30. 2. Huggins CB, Hodges CV. Studies on prostatic cancer. 1.The effect of castration, of estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293 ^ 7. 3. Huggins C. Endocrine-induced regression of cancers. Cancer Res 1967;27:1925 ^ 30. 4. Saitoh H, Hida M, Shimbo T, et al. Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer 1984;54: 3078 ^ 84. 5. Grayhack JT, Keeler TC, Kozlowski JM. Carcinoma of the prostate. Hormonal therapy. Cancer 1987;60: 589 ^ 601. 6. Haranda M, Iida M, Yamaguchi M, et al. Analysis of bone metastasis of prostatic adenocarcinoma in 137 www.aacrjournals.org autopsy cases. In: Prostate cancer and bone metastasis. NewYork: Plenum Press; 1992. p. 173 ^ 82. 7. Bubendorf L, Schopfer A,Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578 ^ 83. 8. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgenindependent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209 ^ 16. 9. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34:646 ^ 53. 10. Feldman BJ, Feldman D.The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34 ^ 45. 11. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366 ^ 81. 1669 12. Debes JD, Tindall DJ. Mechanisms of androgenrefractory prostate cancer. N Engl J Med 2004;351: 1488 ^ 90. 13. Tindall D, Horne FM, Hruszkewycz A, et al. Symposium on androgen action in prostate cancer. Cancer Res 2004;64:7178 ^ 80. 14. Chen CD,Welsbie DS,Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33 ^ 9. 15. Gregory CW, Johnson RT, Jr., Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892 ^ 8. 16.Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91:13 ^ 25. 17. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and Clin Cancer Res 2006;12(6) March 15, 2006 Downloaded from clincancerres.aacrjournals.org on April 30, 2017. © 2006 American Association for Cancer Research. Molecular Pathways progression of human prostate cancer. Nat Genet 1995;9:401 ^ 6. 18. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification:a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314 ^ 9. 19. Linja MJ, Savinainen KJ, Saramaki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550 ^ 5. 20. Latil A, Bieche I, Vidaud D, et al. Evaluation of androgen, estrogen (ER a and ER h), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001;61: 1919 ^ 26. 21. Edwards J, Krishna NS, Grigor KM, et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. BrJCancer 2003; 89:552 ^ 6. 22. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217 ^ 27. 23. Makridakis N, Ross RK, Pike MC, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5a-reductase. Cancer Res 1997;57: 1020 ^ 2. 24. Labrie F, Dupont A, Belanger A, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 1986;7:67 ^ 74. 25. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001 ^ 15. 26. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004;91:483 ^ 90. 27. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989;14:103 ^ 15. 28.Veldscholte J, Berrevoets CA, Ris-Stalpers C, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992;41: 665 ^ 9. 29. Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000;6:703 ^ 6. 30. Buchanan G, Greenberg NM, Scher HI, et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001;7:1273 ^ 81. 31. Shi XB, Ma AH, Xia L, et al. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002;62:1496 ^ 502. 32. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgenindependent prostate cancer. N Engl J Med 1995; 332:1393 ^ 8. 33. TilleyWD, Buchanan G, HickeyTE, et al. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277 ^ 85. 34. Marcelli M, Ittmann M, Mariani S, et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000;60:944 ^ 9. 35. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21:2673 ^ 8. 36. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54: 5474 ^ 8. 37. Culig Z, Steiner H, Bartsch G, et al. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005;95:497 ^ 505. 38. Craft N, ShostakY, Carey M, et al. A mechanism for hormone-independent prostate cancer through mod- ulation of androgen receptor signaling by the HER-2/ neu tyrosine kinase. Nat Med 1999;5:280 ^ 5. 39. Gioeli D, Ficarro SB, Kwiek JJ, et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002;277: 29304 ^ 14. 40. Pienta KJ, Loberg R.The ‘‘emigration, migration, and immigration’’of prostate cancer. Clin Prostate Cancer 2005;4:24 ^ 30. 41. Loberg RD, Logothetis CJ, Keller ET, et al. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005;23:8232 ^ 41. 42. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989;8:98 ^ 101. 43. Janne OA, Moilanen AM, Poukka H, et al. Androgen-receptor-interacting nuclear proteins. Biochem SocTrans 2000;28:401 ^ 5. 44. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315 ^ 9. 45. Li P, Yu X, Ge K, et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 2002;161: 1467 ^ 74. 46. Kang Z, Janne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 2004;18:2633 ^ 48. 47. Wang L, Hsu CL, Chang C. Androgen receptor corepressors: an overview. Prostate 2005;63:117 ^ 30. 48. Fujimoto N,Yeh S, Kang HY, et al. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 1999;274:8316 ^ 21. 49. Ngan ES, HashimotoY, Ma ZQ, et al. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 2003;22:734 ^ 9. 50. Debes JD, SeboTJ, Lohse CM, et al. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63:7638 ^ 40. 51. Comuzzi B, Lambrinidis L, Rogatsch H, et al. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and antiandrogen-induced androgen receptor function. Am J Pathol 2003;162:233 ^ 41. 52. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253 ^ 61. 53. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgenindependent prostate cancer. Cancer Res 1992;52: 6940 ^ 4. 54. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. AmJ Pathol 1993;143:390 ^ 400. 55. Raffo AJ, Perlman H, Chen MW, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55: 4438 ^ 45. 56. FuruyaY, Krajewski S, Epstein JI, et al. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996;2:389 ^ 98. 57. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946 ^ 51. 58. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 2005;55:300 ^ 18. 59. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351: 1502 ^ 12. 60. Tolcher AW, Chi K, Kuhn J, et al. A phase II, pharmacokinetic, and biological correlative study of obli- Clin Cancer Res 2006;12(6) March 15, 2006 1670 mersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005;11:3854 ^ 61. 61. Xu L,Yang D,Wang S, et al. ( )-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 2005;4:197 ^ 205. 62. Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.World J Urol 2005;23:38 ^ 46. 63. BeerTM, Eilers KM, Garzotto M, et al.Weekly highdose calcitriol and docetaxel in metastatic androgenindependent prostate cancer. J Clin Oncol 2003;21: 123 ^ 8. 64. McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr CancerTher 2004;3: 349 ^ 80. 65. Trump DL, Hershberger PA, Bernardi RJ, et al. Antitumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004;89 ^ 90: 519 ^ 26. 66. Strother JM, Beer TM, Dreicer R. Novel cytotoxic and biological agents for prostate cancer : where will the money be in 2005? Eur J Cancer 2005;41: 954 ^ 64. 67. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315:971 ^ 9. 68. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 2005;19:7 ^ 16. 69. Jimeno A, Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev AnticancerTher 2005; 5:419 ^ 27. 70. Banerji U, O’Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23: 4152 ^ 61. 71. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. JClin Oncol 2005;23:1885 ^ 93. 72. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23: 1078 ^ 87. 73. Ramanathan RK,Trump DL, Eiseman JL, et al. Phase I pharmacokinetic-pharmacodynamic study of 17(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385 ^ 91. 74. Eder IE, Culig Z, Ramoner R, et al. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000;7:997 ^ 1007. 75. O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17a-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317 ^ 25. 76. Chang CY, Abdo J, HartneyT, et al. Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol Endocrinol 2005;19:2478 ^ 90. 77. Hewitson KS, Schofield CJ. The HIF pathway as a therapeutic target. Drug Discov Today 2004;9: 704 ^ 11. 78. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91:1420 ^ 4. 79.Wu L, Birle DC,Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005;65:2825 ^ 31. 80. Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1a protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478 ^ 82. www.aacrjournals.org Downloaded from clincancerres.aacrjournals.org on April 30, 2017. © 2006 American Association for Cancer Research. Development of Androgen-Independent Prostate Cancer 81.Vanaja DK, Mitchell SH,Toft DO, et al. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 2002;7:55 ^ 64. 82. Sakowicz R, Finer JT, Beraud C, et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004;64: 3276 ^ 80. 83. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165 ^ 70. 84. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21 ^ 8. 85. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 2004; 96:879 ^ 82. www.aacrjournals.org 86. Winquist E, Berry S. Re: A Randomized, placebocontrolled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2004;96:1183. 87. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805 ^ 13. 88. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940 ^ 5. 89. Bander NH, Milowsky MI, Nanus D, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in 1671 patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591 ^ 601. 90. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004;60:197 ^ 204. 91. Nelson WG, Simons JW, Mikhak B, et al. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 2000;46 Suppl:S67 ^ 72. 92. Kaufman HL,Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22:2122 ^ 32. Clin Cancer Res 2006;12(6) March 15, 2006 Downloaded from clincancerres.aacrjournals.org on April 30, 2017. © 2006 American Association for Cancer Research. Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer Kenneth J. Pienta and Deborah Bradley Clin Cancer Res 2006;12:1665-1671. Updated version Cited articles Citing articles E-mail alerts Reprints and Subscriptions Permissions Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/12/6/1665 This article cites 89 articles, 42 of which you can access for free at: http://clincancerres.aacrjournals.org/content/12/6/1665.full.html#ref-list-1 This article has been cited by 40 HighWire-hosted articles. Access the articles at: /content/12/6/1665.full.html#related-urls Sign up to receive free email-alerts related to this article or journal. To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [email protected]. To request permission to re-use all or part of this article, contact the AACR Publications Department at [email protected]. Downloaded from clincancerres.aacrjournals.org on April 30, 2017. © 2006 American Association for Cancer Research.